Discoid lupus erythematosus (DLE) is a chronic autoimmune condition that primarily attacks the skin, causing coin-shaped patches that can lead to permanent scarring and pigment changes. It is the most common form of cutaneous (skin-limited) lupus and, unlike systemic lupus, typically does not affect internal organs. About 25% of adults with discoid lupus eventually develop systemic lupus, making early diagnosis and consistent treatment important.
How Discoid Lupus Differs From Systemic Lupus
Lupus exists on a spectrum, and discoid lupus sits at the skin-only end. Systemic lupus erythematosus (SLE) is a multisystem disease that can inflame joints, kidneys, the heart, and the brain. Discoid lupus, by contrast, stays confined to the skin in most people. The two conditions share an underlying immune dysfunction, but their day-to-day impact is very different.
That said, the boundary isn’t absolute. A systematic review published in the Journal of Medicine and Life found that roughly 25.4% of adults and 30% of children with discoid lupus progress to systemic disease over time. The risk is higher in people whose lesions spread below the neck (the disseminated form) versus those whose patches stay on the face and scalp.
What the Skin Lesions Look and Feel Like
The hallmark of discoid lupus is a well-defined, round or ring-shaped red patch or raised plaque. Early on, the surface develops a thick, adherent scale. If you peel that scale away, you can see tiny spike-like plugs on its underside, sometimes called the “carpet tack sign.” This is one of the features dermatologists look for during an exam.
Over time, lesions expand outward. The active, inflamed border tends to be darker (hyperpigmented), while the center becomes pale, thinned, and scarred. Small visible blood vessels may appear in the scarred areas. In about 80% of cases, patches are limited to the face, ears, and scalp. The remaining 20% have disseminated disease, with lesions appearing on the chest, arms, or legs as well. Occasionally, discoid patches develop on the lips, inside the nose, or on the genital mucosa.
Many people notice that sun exposure makes things worse. Lesions often follow a “photodistribution,” clustering on sun-exposed skin like the cheeks, nose, and ears.
Scarring and Hair Loss
The most significant long-term consequence of discoid lupus is permanent scarring. Unlike a sunburn that heals and fades, discoid lesions destroy the structures they sit on. When patches develop on the scalp, they can destroy hair follicles entirely, causing scarring alopecia, a type of hair loss that does not grow back. The scarred skin also loses its normal pigment, leaving lighter or darker patches that can be especially noticeable on darker skin tones.
This is why early and consistent treatment matters so much. Once scarring has occurred, the damage is irreversible. The goal of treatment is to control active inflammation before it reaches that point.
Who Gets Discoid Lupus
Women are about twice as likely as men to develop discoid lupus, though the gender gap is narrower than in systemic lupus (where women outnumber men roughly nine to one). Population data from the Manhattan Lupus Surveillance Program found a prevalence of about 6.5 per 100,000 people, with the highest rates in those aged 40 to 59. Women diagnosed with discoid lupus had an average age of about 54, while men tended to be diagnosed younger, around age 40.
Smoking is a notable risk factor. A study of 405 lupus patients found that smokers were significantly more likely to have discoid lupus specifically, with an odds ratio of about 2.0 compared to the general population. Smoking also appears to reduce how well standard treatments work, giving people with discoid lupus a strong practical reason to quit.
How Discoid Lupus Is Diagnosed
Diagnosis starts with a careful look at the skin, but the gold standard is a skin biopsy. Under a microscope, a discoid lupus lesion shows thickened outer skin, plugged hair follicles, damage to the deepest layer of skin cells, and a dense cluster of immune cells in the tissue beneath. A special staining technique called the lupus band test detects immune proteins deposited along the skin’s basement membrane and is positive in about 90% of discoid lupus lesions.
Blood tests play a supporting role. Your doctor will typically order an antinuclear antibody (ANA) screen. A negative ANA makes systemic lupus unlikely, which is helpful for ruling it out. People with discoid lupus that stays skin-limited tend to have lower rates of positive ANA and other lupus-specific antibodies compared to those with systemic disease. Still, a positive ANA alone doesn’t confirm systemic lupus, so the clinical picture and biopsy results carry the most weight.
Treatment Options
Treatment follows a stepwise approach, starting with the least aggressive options and escalating if needed.
- Topical steroids are the first-line treatment for localized patches. Stronger formulations are used on thick, scaly plaques, while milder ones go on thinner skin like the face. These are applied for short periods or on an intermittent schedule because long-term use can thin the skin and cause its own scarring.
- Non-steroidal skin creams (calcineurin inhibitors like tacrolimus) offer an alternative for sensitive areas or when steroids need a break. They suppress the local immune response without thinning the skin.
- Antimalarial medications are the cornerstone of systemic treatment. Hydroxychloroquine, typically dosed at up to 5 mg per kilogram of body weight daily, is the most widely prescribed. It works by calming the overactive immune response driving the skin inflammation. Most people tolerate it well, though it requires periodic eye exams because of a rare risk to the retina with long-term use.
- Additional medications come into play for cases that don’t respond to antimalarials. Options include methotrexate, dapsone, and retinoids, among others. The choice depends on how widespread the disease is and how a person responds to earlier treatments.
Oral steroids are sometimes used short-term for severe flares, but they aren’t a long-term solution because of their side effects.
Triggers to Watch For
Ultraviolet light is the single most consistent trigger. Both UVA and UVB radiation can provoke new lesions or flare existing ones. Broad-spectrum sunscreen with a high SPF, protective clothing, and limiting midday sun exposure are practical steps that make a real difference in flare frequency.
Smoking is the other major modifiable risk factor. Beyond increasing the odds of developing discoid lupus in the first place, tobacco use is associated with poorer treatment response, particularly to hydroxychloroquine. Quitting smoking improves both the likelihood of treatment success and the overall course of the disease.
Monitoring for Systemic Progression
Because roughly one in four adults with discoid lupus eventually develops systemic disease, ongoing monitoring is part of living with this condition. Signs that suggest progression include joint pain or swelling, unexplained fevers, mouth sores that aren’t related to skin patches, fatigue that goes beyond what skin disease alone would explain, or new abnormalities on blood work such as low blood cell counts or rising antibody levels.
Disseminated discoid lupus, where lesions appear both above and below the neck, carries a higher progression risk than the localized form. Children and adolescents with discoid lupus also progress at a higher rate (about 30%) and typically need closer follow-up. Regular check-ins with a dermatologist or rheumatologist, along with periodic blood work, help catch any shift toward systemic involvement early.